A multidisciplinary research team has found a new use for a reliable medical device. Multiple heart patients have already benefited for the group’s outside-the-box thinking.

The high-risk patients who require urgent or emergent TAVR are often excluded from major clinical trials. To learn more about this population, researchers explored data from nearly 600 patients treated at high-volume facilities. 

The first FDA-approved pacing lead specifically developed for LBBAP is now being implanted throughout the United States. 

Several U.S. medical societies have collaborated on a new report advocating for better safety standards in cardiac catheterization labs. As one cardiologist described it, clinicians have shifted from "accepting risk" to "expecting better."

A new acellular tissue-engineered vessel developed by Vascudyne could provide surgeons with a safe, effective alternative to saphenous vein grafts.

Cleveland Clinic, one of the world’s top heart hospitals, has launched a new two-part partnership with Ohio-based DASI Simulations. 

The issue, first announced to the public in February, has been linked to 22 serious injuries. Customers are urged to review the updated instructions for use to avoid any potential complications. 

Students sometimes take unprescribed Adderall to stay up late and study. According to new research out of Mayo Clinic, however, that may do more to the heart than those students realize. 

The group's hope is that these new funds will help address the rising rates of PAD and CLTI throughout the United States.

The system is designed for point-of-care settings such as outpatient offices, sports medicine practices and urgent care clinics.

ImmunityBio, the developer of bladder cancer treatment Anktiva, is accused by the U.S. Food and Drug Administration of disseminating “false or misleading information” about the drug's efficacy in an advertisement and podcast. The FDA said it’s not the first time it's sent a warning letter to the company’s executives over allegedly inaccurate claims.